member
Frank LIU
CO-FOUNDER, orange biotech limited
I was a researcher in the field of CRISPR-based nucleic acid detection with microfluidics, specializing in isothermal detection during my PhD at HKUST. In 2022, my co-founders and I established Orange Biotech. Our motivation was to advance the field of microfluidic CRISPR-based nucleic acid detection and bring it to the point of care testing (POCT) for both routine and emergency applications. We recognized the limitations of existing antigen tests and protein-based diagnostics, as evidenced during the COVID-19 pandemic. Orange Biotech aims to bridge this gap by providing highly sensitive and specific products that can match the level of lab-based PCR testing while maintaining the simplicity and ease of use associated with rapid antigen tests. We firmly believe that decentralized diagnostics, available at any time and anywhere, will play a crucial role in disease prevention and large-scale screening. As a company specializing in isothermal detection, we are committed to offering a wide range of products to both institutional clients and individuals. Our goal is to contribute to the advancement of telemedicine and facilitate the key steps necessary for the near-future transformation of healthcare.
Company Description
Orange Biotech, founded in 2022, is dedicated to addressing the critical issues of disease prevention and large-scale screening. By combining microfluidics and CRISPR-based diagnostics, we develop advanced nucleic acid detection applications for single and multiplexed tests. Our expertise lies in creating all-in-one, integrated, and cost-effective Point of Care Testing (POCT) products for home-based nucleic acid tests, targeting sexually transmitted diseases and respiratory infections. In addition to our individual testing kits, we are actively developing a centralized platform to facilitate large-scale population screening. This innovative platform enables efficient and highly sensitive nucleic acid detection, promoting early screening and timely intervention. By harnessing the power of multiplexed testing, we aim to streamline the diagnostic process and make it more accessible to the general public. Our ultimate goal is to provide individuals with easier and more affordable options for nucleic acid testing, particularly for early disease screening, prevention, and re-examination. We cater to all people with health concerns, striving to transform the landscape of healthcare and empower individuals to take charge of their well-being.